PFS
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
PFS
Sep 1, 2024, 09:48 |
Insight
Phase III Keynote-789 Trial of Platinum + Pemetrexed +/- Pembrolizumab in EGFR + NSCLC
Jarushka Naidoo shared a post on X: "Phase III Keynote-789 Trial of Platinum + Pemetrexed +/-Pembro…
Aug 17, 2024, 08:51 |
Insight
Haryana Dhillon: Adjusting to unexpected survivorship after exceptional response to cancer treatment
Haryana Dhillon, Associate Professor of Psychology at University of Sydney, shared on X a recent…
Aug 4, 2024, 06:32 |
Insight
Elad Sharon: One of my favorite recent efforts from the SWOG Cancer Research Network's DART trial - a look at linear change in tumor size
Elad Sharon, Clinical and Translational Director at Dana-Farber Cancer Institute, shared JNCI's (Journal of the…
Jul 9, 2024, 06:35 |
Blog
Rahul Banerjee: Nice analysis of Australia/New Zealand multiple myeloma with emphasis on CRAB vs SLiM
Rahul Banerjee, Assistant Professor at UW Medicine, made the following post on X: “Now in The…
Jul 8, 2024, 14:02 |
Insight
Real world outcomes with durvalumab after chemoradiation for stage III NSCLC in an elderly population
Stephen Liu, shared a post on X about a recent paper titled "Real-World Efficacy and…
Jul 7, 2024, 17:43 |
Insight
Jarushka Naidoo: ctDNA+ associates with outcomes in stage III unresectable NSCLC
Jarushka Naidoo shared a post on X: “ctDNA+ in consolidation IO trial (BTCRC 16-081) associates…
Jul 1, 2024, 14:03 |
Drugs
Robert Jotte presents how Adagrasib shows improvement in PFS and ORR in previously treated patients - Sarah Cannon Research Institute
Sarah Cannon Research Institute shared on LinkedIn: "Significant advancements in NSCLC treatment! SCRI's Dr. Robert Jotte…
Jun 29, 2024, 13:39 |
Insight
Myeloma Paper of the Day, June 29th, suggested by Robert Orlowski
Robert Orlowski shared on X: "Myeloma Paper of the Day: Real-world analysis of renally impaired…
Jun 26, 2024, 03:52 |
Opinion
Alexandros Alexandropoulos: Some thoughts on Multiple Melanoma clinical trials practice and restrictions
Alexandros Alexandropoulos, Hematologist at Laiko General Hospital, shared a post on X: "Some thoughts on Multiple…
Jun 24, 2024, 22:56 |
Blog
Giovanni Marchegiani: Perioperative modified FOLFIRINOX for pancreas cancer
Giovanni Marchegiani, Pancreas Surgeon at The University of Padua, made the following post on X:…
Jun 23, 2024, 04:34 |
Insight
Ashish Kamat: IBCG scoring system and substratification model for IR NMIBC
Ashish Kamat, Endowed Professor of Urologic Oncology (Surgery) and Cancer Research at University of Texas MD…
Jun 8, 2024, 09:58 |
Insight
Angelo Pirozzi: Circulating immune-related proteins might predict the efficacy of Immune Checkpoint Inhibitors
Angelo Pirozzi, Research Fellow at Mayo Clinic, shared on X: .…
Jun 7, 2024, 14:45 |
Blog
Manni Mohyuddin on DREAMM-7
Manni Mohyuddin shared on X/Twitter: "In DREAMM-7 (bela/bort/dex vs dara/bort/dex). Only 34% of pts len refractory.…
Jun 5, 2024, 11:36 |
Blog
Bishal Gyawali: An important clarification for the ASCO24 audience regarding PFS
Bishal Gyawali, Associate Professor at Queen’s University, shared on X/Twitter: "An important clarification for the ASCO24…
Jun 4, 2024, 04:25 |
Blog
Cathy Eng: Phase 3 Checkmate 8HW update from Dr. Lenz
Cathy Eng shared a post on X: "Ph 3 Checkmate 8HW update from Dr. Lenz…
May 28, 2024, 08:21 |
Blog
Antonio Passaro's top 10 selection with explanation, among the lung cancer abstracts from ASCO24
Antonio Passaro, shared a post on X: ''ASCO24 is ready to start soon! Here, my top…
May 18, 2024, 08:47 |
Blog
Elisa Agostinetto: At ESMO Breast24, Hope Rugo presents results of CAPItello-291
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on X/Twitter: ''At…
May 18, 2024, 04:17 |
Blog
Sara Tolaney: Interesting data from Mafalda Oliveira from SERENA-2 at ESMO Breast24
Sara Tolaney shared a post on X: ''Interesting data from Mafalda Oliveira from SERENA-2 demonstrating…
May 18, 2024, 04:13 |
Blog
Elisa Agostinetto: Is this a new predictive biomarker for PFS with camizestrant
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on X/Twitter: ''At…
May 16, 2024, 02:34 |
Blog
Dr. Domenica Lorusso discussed the survival analysis of the PAOLA1 trial - International Journal of Gynecological Cancer
International Journal of Gynecological Cancer shared on LinkedIn: "New episode of Weekly Podcast Dr. Domenica…
May 9, 2024, 00:16 |
Insight
Update CheckMate 9ER summarized by Sergio Cifuentes
Sergio Cifuentes, Cancer Research Project Manager at CENEIT México, posted on X: “Update CheckMate 9ER - PFS:…
Apr 22, 2024, 17:31 |
Blog
Angela Mastronuzzi: A trip to the vibrant Memphis for Posterior Fossa Society's global meeting!
Angela Mastronuzzi shared on LinkedIn: "A trip to the vibrant Memphis for Posterior Fossa Society's global…
Apr 8, 2024, 16:20 |
Drugs
Rami Manochakian: BIG NEWS press release by AstraZeneca!
Rami Manochakian, Thoracic Medical Oncologist at Mayo Clinic, shared a post on X: “Hot Off…
Mar 14, 2024, 19:28 |
Drugs
François-Clément Bidard: A prospective study to document the efficacy of the combo Fulvestrant+Everolimus
Erika Hamilton, Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, shared…
Feb 25, 2024, 14:57 |
Blog
Robert Francomano: Significant change in regulatory priorities by the FDA
Robert Francomano, Chief Commercial Officer at SELLAS, shared on LinkedIn: "The recent emphasis by the…
Dec 17, 2023, 16:45 |
Opinion
Manni Mohyuddin: Sad to see surrogacy word loosely used in a plenary session
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, recently…
Dec 14, 2023, 15:41 |
Insight
Samer Al Hadidi: Will use of CAR-T earlier be better?
Samer Al Hadidi, Assistant Professor at UAMS Myeloma Center, made the following post on X/Twitter:…
Oct 28, 2023, 16:36 |
Insight
Vinay Prasad: The most interesting thing you'll read about PFS, EFS, DFS in oncology this year
Vinay Prasad, Professor of Epidemiology and Biostatistics at University of California, shared a post by…
Jun 19, 2023, 19:57 |
Drugs
FOLFOXIRI only adds 1.6 months PFS but increases toxicity significantly - Enrique Soto
Interesting results FOLFOXIRI only adds 1.6 months PFS but increases toxicity significantly (7 toxic…
All:
29
Posts:
1 - 100
Making Personal Experience a Political Priority: Insights from EU Commissioner Stella Kyriakides
Zolbetuximab is now approved by the US FDA
Highlights from NFCR’s GSAC24
SIOP Honoured Hansjörg Riehm with the 2024 Lifetime Achievement Award
Margaret Foti has received the 2024 Beacon Award for Women Leaders in Oncology
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube